The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Bisphosphonate-Induced Osteopetrosis
Open accessAbstract
isphosphonates, synthetic analogues of inorganic pyrophosphate, potently inhibit skeletal resorption by suppressing the recruitment and activity of osteoclasts and shortening their life span. 1 Consequently, several bisphosphonates were developed to treat hypercalcemia (associated with cancer), osteoporosis, and Paget's disease of bone and are used for additional disorders in adults. 1 Increasingly, bisphosphonates are being administered to children [2][3][4] and have been reported to improve clinical outcomes and augment bone mass in conditions such as osteogenesis imperfecta, 5 juvenile osteoporosis, 2 and fibrous dysplasia, 6 although controlled studies of these compounds in children are lacking.3,4,7 Genetic defects that abrogate the action of osteoclasts cause osteopetrosis, which is characterized by dense, poorly formed, and brittle skeletal tissue.8 Acquired osteopetrosis, or marble bone disease, could therefore result from treatment with bisphosphonates during growth.Here, we document a case of drug-induced osteopetrosis.A 12-year-old white boy, referred to us for unexplained skeletal pains and markedly elevated serum alkaline phosphatase activity, first began to limp as a result of left-hip discomfort after unobserved playground trauma at the age of 5 years.The symptoms subsequently became intermittent but intensified and included pain deep in the left thigh and leg.A finding of hyperphosphatasemia (alkaline phosphatase level, approximately 1400 U per liter; normal level, <350), reflecting bone alkaline phosphatase, prompted a biochemical assessment of mineral homeostasis, skeletal radiography and scintigraphy, and magnetic resonance imaging.Only possible synovitis of the left hip was identified.Nevertheless, the child's condition improved little with analgesics and nonsteroidal antiinflammatory drugs.At six years of age, his right distal radius healed uneventfully after substantial trauma; however, his fingertips also reportedly broke after a minor injury.At 7 1 ⁄ 2 years of age, the results of dual-energy x-ray absorptiometry were interpreted as showing low density of the lumbar spine, although the z score was ¡1.0.Extensive investigations included tests for osteogenesis imperfecta, lysosomal storage diseases, rheumatologic diseases, mitochondrial-gene defects, and aminoaciduria, all of which were negative.The results of karyotyping and electromyography with nerve-conduction velocity were normal.Bone antiresorptive therapy was begun with intranasal salmon calcitonin daily for one month to treat "idiopathic hyperphosphatasia," yet urinary excretion of total hydroxyproline was 58 mg per day (442 µmol per day; normal level, 23 to 77 mg [175 to 587 µmol] per day), and the serum osteocalcin level was 12 ng per milliliter (normal level, 18 to 24), reflecting no acceleration of skeletal turnover.The boy's pain diminished, but serum alkaline phosphatase activity did not decrease.Soon after, discomfort provoked by exercise intensified and included his right lower limb.At 7 3 ⁄ 4 years of age, his antiresorptive treatment was changed to pamidronate (Aredia, Novartis).Initially, a dose of 10 mg (0.37 mg per kilogram of body weight) infused intravenously on three consecutive days seemed to diminish the intensity, duration, and b case report
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta
Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391402 · Cited by 1,015
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Bachrach, L. K., Hastie, T., Wang, M.-C., Narasimhan, B., & Marcus, R. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6182 · Cited by 508
Osteoprotegerin Deficiency and Juvenile Paget's Disease
Whyte, M. P., Obrecht, S. E., Finnegan, P. M., Jones, J. L., Podgornik, M. N., McAlister, W. H., & Mumm, S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013096 · Cited by 445
Self-citationCleiren, E. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.25.2861 · Cited by 373
Bachrach, L. K. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.12.4702 · Cited by 338
Brumsen, C., T. Hamdy, N. A., & Papapoulos, S. E. (1997) · Medicine · doi:10.1097/00005792-199707000-00005 · Cited by 272
Rauch, F., Travers, R., Plotkin, H., & Glorieux, F. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215952 · Cited by 250
Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease
Kinoshita, A., Saito, T., Tomita, H.-A., Makita, Y., Yoshida, K., Ghadami, M., Yamada, K., Kondo, S., Ikegawa, S., Nishimura, G., et al. (2000) · Nature Genetics · doi:10.1038/79128 · Cited by 249
Cited by
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
Seeman, E., & Delmas, P. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra053077 · Cited by 2,080
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Marx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.07.010 · Cited by 1,648
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Rauch, F., & Glorieux, F. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16051-0 · Cited by 1,167
Osteoclasts: What Do They Do and How Do They Do It?
Teitelbaum, S. L. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060834 · Cited by 730
Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION
Goh, S.-K., Yang, K. Y., Koh, J. S. B., Wong, M. K., Chua, S. Y., Chua, D. T. C., & Howe, T. S. (2007) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.89b3.18146 · Cited by 513
Tolar, J., Teitelbaum, S. L., & Orchard, P. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040952 · Cited by 506
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Migliorati, C. A., Schubert, M. M., Peterson, D. E., & Seneda, L. M. (2005) · Cancer · doi:10.1002/cncr.21130 · Cited by 489
Managing the care of patients with bisphosphonate-associated osteonecrosis
MIGLIORATI, C. A., CASIGLIA, J., EPSTEIN, J., JACOBSEN, P. L., SIEGEL, M. A., & WOO, S.-B. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0108 · Cited by 468
Low Magnitude Mechanical Loading Is Osteogenic in Children With Disabling Conditions
Ward, K., Alsop, C., Caulton, J., Rubin, C., Adams, J., & Mughal, Z. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040129 · Cited by 432
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Bisphosphonate therapy for osteogenesis imperfecta
Dwan, K., Phillipi, C. A., Steiner, R. D., & Basel, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005088.pub4 · Cited by 405
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
Lenart, B. A., Neviaser, A. S., Lyman, S., Chang, C. C., Edobor-Osula, F., Steele, B., van der Meulen, M. C. H., Lorich, D. G., & Lane, J. M. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0805-x · Cited by 384
Gilsanz, V., Wren, T. A., Sanchez, M., Dorey, F., Judex, S., & Rubin, C. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060612 · Cited by 370
Management of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T., & Stiff, P. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj105 · Cited by 301
Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?
Hellstein, J. W., & Marek, C. L. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.01.010 · Cited by 270
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
Visekruna, M., Wilson, D., & McKiernan, F. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2803 · Cited by 270
Tat, S. K., Padrines, M., Theoleyre, S., Couillaud-Battaglia, S., Heymann, D., Redini, F., & Fortun, Y. (2006) · Bone · doi:10.1016/j.bone.2006.03.016 · Cited by 63
“However, although the efficiency of bisphosphonate treatment is clearly demonstrated in inhibiting bone resorption, several secondary and undesirable side effects have been recently reported [29–31].”
BackgroundZauli, G., Rimondi, E., Stea, S., Baruffaldi, F., Stebel, M., Zerbinati, C., Corallini, F., & Secchiero, P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21165 · Cited by 63
Metadata
- Authors
- Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-31
- Volume
- 349
- Issue
- 5
- Pages
- 457-463
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115785458
- Cited by
- 446
- References
- 17
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.